Fennec Pharmaceuticals Expands Clinical Data on PEDMARK at 2026 ASCO Meeting
Event summary
- Four abstracts on PEDMARK® (sodium thiosulfate injection) accepted for 2026 ASCO Annual Meeting.
- Studies focus on cisplatin-induced hearing loss in pediatric, adolescent, and adult cancer patients.
- PEDMARK® is FDA-approved for reducing ototoxicity in pediatric patients with localized solid tumors.
- NCCN recommends PEDMARK® for adolescent and young adult patients with a 2A endorsement.
- Full abstracts available on ASCO website from May 21, 2026.
The big picture
Fennec Pharmaceuticals is positioning PEDMARK® as a critical solution for cisplatin-induced hearing loss, a significant unmet need in oncology. The acceptance of multiple abstracts at ASCO underscores growing clinical interest and the urgency to address ototoxicity in cancer treatment. With Norgine Pharmaceuticals leading commercialization efforts in key markets, Fennec aims to solidify its role in reducing treatment-related complications for cancer patients.
What we're watching
- Clinical Validation
- How the ASCO abstracts will influence the adoption of PEDMARK® in broader cancer patient populations.
- Regulatory Expansion
- Whether Fennec can secure additional approvals for PEDMARK® in adult cancer patients based on new data.
- Commercial Strategy
- The pace at which Norgine Pharmaceuticals can expand PEDMARQSI® commercialization in Europe and other regions.
Related topics